Keros Plummets 73% After Unexpected Side Effects ‘Shock’ Its Lead Drug

Keros Therapeutics stock plummeted Thursday after the company stopped giving higher doses in a lung disease study due to side effects.

Leave a Reply

Your email address will not be published. Required fields are marked *

0 Comments
scroll to top